Company Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer’s disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD.
The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson’s disease; and ACI-35.030, designs to stimulate a patient’s immune system to produce antibodies against pathological phosphorylated Tau.
In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease.
Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies.
Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3.
The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company.
AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
| Country | Switzerland |
| Founded | 2003 |
| IPO Date | Sep 23, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 172 |
| CEO | Andrea Pfeifer |
Contact Details
Address: Building B, EPFL Innovation Park Lausanne, 1015 Switzerland | |
| Phone | 41 21 345 91 21 |
| Website | acimmune.com |
Stock Details
| Ticker Symbol | ACIU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| CIK Code | 0001651625 |
| CUSIP Number | H00263105 |
| ISIN Number | CH0329023102 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrea Pfeifer Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Christopher Roberts | Chief Financial Officer and Vice President of Finance |
| Piergiorgio Donati | Chief Technical Operations Officer |
| Howard Donovan | Chief Human Resources Officer |
| Dr. Gary Anthony Waanders Ph.D. | Senior Vice President of Investor Relations and Corporate Communications |
| Dr. Matthias Maurer Ph.D. | SVice President and General Counsel |
| Dr. Oliver Sol M.D. | Vice President and Head of Clinical Development |
| Dr. Julien Rongere Ph.D. | Senior Vice President of Regulatory Affairs and Quality Assurance |
| Mark Danton | Executive Vice President of Information Systems and Artificial Intelligence |
| Dr. Günther Staffler Ph.D. | Interim Executive Vice President of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 5, 2025 | 6-K | Report of foreign issuer |
| Jul 24, 2025 | 144 | Filing |
| Jun 20, 2025 | 6-K | Report of foreign issuer |
| Jun 11, 2025 | 6-K | Report of foreign issuer |
| May 19, 2025 | 6-K | Report of foreign issuer |
| Apr 30, 2025 | 6-K | Report of foreign issuer |
| Mar 13, 2025 | 6-K | Report of foreign issuer |
| Mar 13, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Dec 18, 2024 | 6-K | Report of foreign issuer |
| Dec 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |